Trial Profile
Randomized, Double-Blinded, Placebo-Controlled, Parallel-Design, Dose-Range Finding Study of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Study P05495)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Tildrakizumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme; Schering-Plough Research Institute
- 12 Mar 2020 Results (n=2167) of pooled analysis from NCT01225731, NCT01722331, NCT01729754; evaluating the dosing regimen for tildrakizumab, in moderate-to-severe chronic plaque psoriasis patients, published in the British Journal of Clinical Pharmacology
- 27 Mar 2019 Results evaluating anti-drug antibody (ADA) development in chronic plaque psoriasis subjects from 3 clinical trials of tildrakizumab, a humanized anti-IL-23p19 monoclonal antibody (P05495, reSURFACE 1, and reSURFACE 2) published in the British Journal of Dermatology
- 26 Mar 2019 Results of population pharmacokinetic modeling of Tildrakizumab in healthy volunteers and subjects with psoriasis published in the Clinical Pharmacokinetics